Search Results

Karius®, Inc. announced today that the Karius Test® has been granted designation as a Breakthrough Device from The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA), for use in the diagnosis and management of immunocompromised patients with suspected lung infections including lower respiratory infection and pneumonia.

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, announced it has secured $100 million in Series C funding.

Although U.S. full-time employees worked an average of 42.9 hours weekly last year, according to Gallup, that wasn’t true for most BioSpace LinkedIn poll respondents. A Karius HR executive discusses a few potential reasons for the longer workweeks.

Karius®, Inc. a world leader in liquid biopsy for infectious diseases, has announced the inaugural inclusion of the Karius Test® in the 2023 Duke-ISCVID Criteria for Infective Endocarditis by the International Society of Cardiovascular Infectious Diseases.

A pivotal multi-center study published in Clinical Infectious Diseases demonstrates the effectiveness of the Karius Test®, a blood test based on metagenomics next generation sequencing of microbial cell-free DNA, by increasing the identification of pathogens causing pneumonia in immunocompromised patients by 40% (20/52) when combined with usual care diagnostic testing1.

Karius® and eGenesis, Inc. a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced a partnership through which the two companies will develop infectious disease diagnostics for xenotransplantation initially from porcine to primates and ultimately to humans.

Karius ® , Inc. a world leader in liquid biopsy for infectious diseases, is announcing the appointment of two healthcare veterans to its Board of Directors: Norman (Ned) Sharpless, M.D. and Elizabeth (Liz) O’Farrell.

Karius®, the world leader in liquid biopsy for infectious diseases, today announced a partnership with Capstone Health Alliance, a group purchasing organization focused on supply chain savings in hospitals and other organizations, to streamline patient access to the Karius Test®.

Karius, the world leader in liquid biopsy for infectious diseases, announced the addition of two key executives to best position the company for continued growth.

Karius has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP) for its Karius Test for pathogen detection.